Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan;66(1):107-12.
doi: 10.1136/ard.2006.052647. Epub 2006 May 25.

Progression of salivary gland dysfunction in patients with Sjogren's syndrome

J Pijpe  1 , W W I Kalk, H Bootsma, F K L Spijkervet, C G M Kallenberg, A Vissink
Affiliations

Progression of salivary gland dysfunction in patients with Sjogren's syndrome

J Pijpe et al. Ann Rheum Dis. 2007 Jan.

Abstract

Background: Salivary gland dysfunction is one of the key manifestations of Sjögren's syndrome.

Objectives: (1) To assess prospectively loss of function of individual salivary glands in patients with primary and secondary Sjögren's syndrome in relation to disease duration and use of immunomodulatory drugs. (2) To study changes in sialochemical and laboratory values and subjective complaints over time.

Methods: 60 patients with Sjögren's syndrome were included in this study. Whole and gland-specific saliva (parotid and submandibular/sublingual (SM/SL)), samples were collected at baseline and after a mean of 3.6 (SD 2.3) years of follow-up. Disease duration was recorded for all patients.

Results: Patients with Sjögren's syndrome with short disease duration had significantly higher stimulated flow rates at baseline than those with longer disease duration (p<0.05). When compared with healthy controls, the decrease in SM/SL flow rates at baseline was more prominent than that in parotid flow rates (p<0.05). Over time, there was a significant further decrease of stimulated flow rates, especially of the parotid gland, accompanied by increasing problems with swallowing dry food (p<0.05). The decrease was independent of the use of corticosteroids or disease-modifying antirheumatic drugs (DMARDs). Sialochemical variables remained stable.

Conclusions: Early Sjögren's syndrome is characterised by a decreased salivary gland function (parotis>SM/SL), which shows a further decrease over time, regardless of the use of DMARDs or steroids. Patients with Sjögren's syndrome with longer disease duration are characterised by severely reduced secretions of both the parotid and SM/SL glands. These observations are relevant for identifying patients who would most likely benefit from intervention treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mignogna M D, Fedele S, Russo L L, Lo Muzio L, Wolff A. Sjögren's syndrome: the diagnostic potential of early oral manifestations preceding hyposalivation/xerostomia. J Oral Pathol Med 2005341–6. - PubMed
    1. Thorn J J, Prause J U, Oxholm P. Sialochemistry in Sjögren's syndrome: a review. J Oral Pathol Med 198918457–468. - PubMed
    1. Kalk W W I, Vissink A, Spijkervet F K L, Bootsma H, Kallenberg C G M, Nieuw Amerongen A V. Sialometry and sialochemistry: diagnostic tools for Sjögren's syndrome. Ann Rheum Dis 2001601110–1116. - PMC - PubMed
    1. Veerman E C I, Van den Keybus P A, Vissink A, Nieuw Amerongen A V. Human glandular salivas: their separate collection and analysis. Eur J Oral Sci 1996104346–352. - PubMed
    1. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos H M, Alexander E L, Carsons S E.et al Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American‐European Consensus Group. Ann Rheum Dis 200261554–558. - PMC - PubMed

MeSH terms

-